| Study period | Follow-up | ||||||
---|---|---|---|---|---|---|---|---|
Time point | Screening | D0 | D1 | D2 | D3 | D4 | D5 | D28 |
Number of visits | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
Eligibility criteria | x | Â | Â | Â | Â | Â | Â | Â |
Informed consent | x | Â | Â | Â | Â | Â | Â | Â |
Allocation | x | Â | Â | Â | Â | Â | Â | Â |
Demographic data | Â | x | Â | Â | Â | Â | Â | Â |
APACHE II | Â | x | Â | Â | Â | Â | Â | Â |
SOFA score | Â | x | Â | Â | Â | Â | Â | Â |
Laboratory tests (total serum protein, albumin, prealbumin) | Â | x | Â | Â | Â | Â | x | Â |
Estimation of energy and protein target | Â | x | Â | Â | Â | Â | Â | Â |
Administration of enteral nutrition | Â | Â | x | x | x | x | x | Â |
Assessment of tolerance (diarrhea, vomiting, GRV, postpyloric nutrition) | Â | Â | x | x | x | x | x | Â |
Assessment of complications | Â | Â | x | x | x | x | x | Â |
Assessment of energetic and protein targets | Â | Â | x | x | x | x | x | Â |
Assessment of hospital LOS, ICU LOS, and mortality | Â | Â | Â | Â | Â | Â | Â | x |